PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 54: Integrating connectivity mapping resources to prioritize and personalize drug candidates for individual triple negative breast cancer patients.

View Full Paper
Ask AI
Bookmark
Share

Authors

LTLily TaubABAnna I. ByrdDCDaniel Clarke

Discussion

Loading...

Member takes

Overview

This approach identifies drug candidates for individual triple negative breast cancer tumors, suggesting personalized treatment options.

Key Points

  • The research aims to personalize drug candidates for triple negative breast cancer (TNBC) patients by integrating connectivity mapping resources.
  • Analyzed RNA-seq samples from primary TNBC tumors and matched PDX models.
  • Identified differentially expressed genes in TNBC compared to normal tissues.
  • Used DepMap to examine the impact of knocking out up-regulated genes on cell viability.
  • Integrated five connectivity mapping resources to identify compounds that may down-regulate target genes.
  • Developed an online tool (Dr. Gene Budger 2.0) to suggest patient-specific therapeutic compounds.
  • Identified candidate drugs that may inhibit tumor growth in individual TNBC patients.
  • Predicted down-regulation of key tumor-associated genes with specific drugs.
  • Validated connections between gene expression and drug response using multiple datasets.

Cite This Study

Taub et al. (2026) studied this question.

synapsesocial.com/papers/69d1fcc0a79560c99a0a269bhttps://doi.org/10.1158/1538-7445.am2026-54
View Full Paper
Ask AI
Bookmark
Share